Skip to main content
. 2016 Mar 15;114(6):669–679. doi: 10.1038/bjc.2016.40

Figure 4.

Figure 4

Simulations of the PK/biomarker/tumour growth model for four long-term dosing scenarios: (A) vemurafenib 15 mg kg−1 twice a day given continuously, (B) vemurafenib 15 mg kg−1 twice a day and abemaciclib 50 mg kg−1 every day in combination, both given continuously, (C) vemurafenib 15 mg kg−1 twice a day given on an intermittent 2 weeks on/1 week off schedule, (D) intermittent vemurafenib 15 mg kg−1 twice a day in combination with continuous abemaciclib 50 mg kg−1 every day.